Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Deferred Taxes (2023 - 2025)

Gyre Therapeutics (GYRE) has disclosed Deferred Taxes for 3 consecutive years, with -$87000.0 as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 85.3% to -$87000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, down 10.68% year-over-year, with the annual reading at -$1.1 million for FY2025, 10.68% down from the prior year.
  • Deferred Taxes for Q4 2025 was -$87000.0 at Gyre Therapeutics, up from -$531000.0 in the prior quarter.
  • The five-year high for Deferred Taxes was -$87000.0 in Q4 2025, with the low at -$592000.0 in Q4 2024.
  • Average Deferred Taxes over 3 years is -$297363.6, with a median of -$300000.0 recorded in 2025.
  • Peak annual rise in Deferred Taxes hit 85.3% in 2025, while the deepest fall reached 209.28% in 2025.
  • Over 3 years, Deferred Taxes stood at -$403000.0 in 2023, then tumbled by 46.9% to -$592000.0 in 2024, then skyrocketed by 85.3% to -$87000.0 in 2025.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at -$87000.0, -$531000.0, and -$300000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.